• Histologically-confirmed locally advanced or metastatic prostate cancer. Patients with unequivocal clinical evidence supporting diagnosis of prostate cancer who have not had prior biopsy may be considered eligible per judgment of Principal Investigator.

• Presence of at least one target lesion detected by standard staging scans that, in the judgment of Study Investigators, would be amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging:

‣ Soft tissue/visceral organ target lesions must measure at 1 cm in long axis diameter on CT or MRI.

⁃ Target lesions in the bone must be visualized by CT or MRI (lesions present only on bone scan do not qualify).

⁃ For patients with target lesion in prostate/prostatic bed:

• i. No contra-indications to endorectal coil insertion (e.g., patients with a prior abdominoperineal resection of the rectum or latex allergy).

• ii. No prior local treatment to the selected lesion, or evidence of radiographic progression following prior local therapy to selected lesion.

• Able and willing to comply with study procedures and provide signed and dated informed consent.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

• For patients undergoing optional tumor biopsy:

‣ No history of bleeding diathesis.

⁃ Patients on anti-coagulation they must be able to safely stop treatment for purposes of tumor biopsy.